Background: Continuous intravenous administration of landiolol has been performed in supraventricular tachycardia (SVT) patients for heart rate (HR) control. SVT includes atrial fibrillation (af) and atrial flutter (AFL), though effectiveness of landiolol on these different arrhythmias are still unclear. Methods: We enrolled 98 consecutive patients with SVT who received landiolol from January 2012 to December 2016. Successful HR control was defined as >20% reduction in baseline HR or with HR < 110 bpm at 2 hours after starting landiolol. We divided the subjects into group A (af, n = 88) and F (AFL, n = 10). HR control level, conversion of normal sinus rhythm (NSR), merger rate of heart failure (HF), laboratory and echocardiographic findings were compared. These findings were also compared to HF patients. Results: The mean HR at baseline were 136.7 ± 21.4 bpm and 142.2 ± 19.7 bpm in group A and F, respectivilty. HR was successfully controlled in 69.3% and 20.0% in group A and F (P < .001). NSR was achieved in 19 patients of group A, and none in group F. Merger rate of HF were 83% and 60% respectively (P = .042). In laboratory and echocardiographic findings, only BNP in group A was significantly higher than group F (727.1 ± 504.5 pg/mL and 390.8 ± 279.4 pg/mL, P = .021). The results were similar in patients with HF. Conclusion: It is important to give thoughts to the type of arrhythmia when administrating landiolol for SVT.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of Cardiac Failure
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect